Abstract: The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics.

Abstract: Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed and methods of using such formulations are further provided.

Abstract: The present invention is directed to novel Anti-TNF? antibody binding compounds and methods of using the same. Anti-TNF? antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF? antibody binding compound. The invention further provides the use of an Anti-TNF? antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.

Abstract: The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.

Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics.

Abstract: The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics. Specifically, the methods comprising synthesizing a single substitution library for each of a plurality of domains of a protein; expressing separately each member of each single substitution library as a pre-candidate protein; selecting members of each single substitution library which encode pre-candidate proteins which exhibit an improvement in the one or more predetermined characteristics to form a selected library; shuffling members or the selected libraries in a PCR to produce a combinatorial shuffled library; expressing members of the shuffled library as candidate proteins; and selecting mutant proteins which have improved properties or characteristics.

Abstract: The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.

Abstract: The invention provides efficient methods for combining single-substitution libraries of nucleic acids that span and encode proteins of interest and for selecting resultant mutant proteins after expression which have improved properties or characteristics. Specifically, the methods comprising synthesizing a single substitution library for each of a plurality of domains of a protein; expressing separately each member of each single substitution library as a pre-candidate protein; selecting members of each single substitution library which encode pre-candidate proteins which exhibit an improvement in the one or more predetermined characteristics to form a selected library; shuffling members or the selected libraries in a PCR to produce a combinatorial shuffled library; expressing members of the shuffled library as candidate proteins; and selecting mutant proteins which have improved properties or characteristics.

Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Abstract: The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.

Abstract: The present invention is directed to novel Anti-TNF? antibody binding compounds and methods of using the same. Anti-TNF? antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNF? antibody binding compound. The invention further provides the use of an Anti-TNF? antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.

Abstract: The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.

Abstract: The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

Abstract: The invention is directed to a method for analyzing the competitive binding and target (or ligand) specificity of large numbers of candidate binding compounds with respect to a predetermined reference compound. That is, the invention provides a method for essentially conducting a massively parallel ELISA on each member of an entire library of candidate binding compounds at the same time. Instead of determining binding characteristics from a series of colorimetric or fluorometric readouts, such characteristics are determined from a series of frequencies of bound and unbound library members which, in turn, are determined by high-throughput sequencing of their encoding nucleic acids. In one aspect, predetermined reference compounds are proteins and candidate binding compounds are members of a mutant library based on or related to, the predetermined reference compound.

Abstract: The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

Abstract: The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

Abstract: The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

Abstract: The invention is directed to methods for simultaneously improving a plurality of characteristics of a protein binding compound. In accordance with one aspect of the invention, a focused library of nucleic acid-encoded variants is produced and separately exposed to a plurality of reaction conditions each designed to segregate the library variants according to a different characteristic of interest, such as affinity, stability, cross-reactivity, or the like. In various embodiments, such reactions may be conducted pair-wise to simultaneously obtain improvements in two characteristics or they may be conducted three-at-a-time to simultaneously obtain improvements in three characteristics. In each case, nucleotide sequences encoding library variants segregated into improved subsets are determined, after which sequences occurring in two or more subsets are identified to obtain library variants with two or more improved characteristics.

Abstract: Disclosed are mammalian expression vectors for expressing simultaneous expression of immunoglobulins as both a secreted and cell surface bound form.